P1-0340 — Final report
1.
In vitro activity of LK-157, a novel tricyclic carbapenem as broad-spectrum beta-lactamase inhibitor.

LK-157 is a novel tricyclic carbapenem with potent activity against class A and class C ß-lactamases. When tested against the purified TEM-1 and SHV-1 enzymes, LK-157 exhibited 50% inhibitory concentrations (IC50s) in the ranges of the clavulanic acid and tazobactam IC50s (55 nM and 151 nM, respectively).

F.02 Acquisition of new scientific knowledge

COBISS.SI-ID: 1374812
2.
Antibacterial combination of a tricyclic carbapenem and an antibiotic

Combination therapy of tricyclic carbapenems with different antibiotics has been patented.

F.02 Acquisition of new scientific knowledge

COBISS.SI-ID: 4059418
3.
Use of AZA-phenylalanine compounds for treating cardiac arrhythmia :

Novel, unexpected antiarrhythmic activity of azaphenyllanine trmbin inhibitors has been patented

F.02 Acquisition of new scientific knowledge

COBISS.SI-ID: 24440025
4.
Improved affinity selection of ligands from phage-displayed libraries

Improved affinity selection of ligands from phage-displayed libraries has been patented and the new approach enables serching fro new peptide ligands fro diverse molecular targets

F.02 Acquisition of new scientific knowledge

COBISS.SI-ID: 2271345
5.
Design and synthesis of novel cholesterol biosynthesis inhibitors :

Design, synthesis and evaluation of novel, non-statin cholesterol biosynthesis inhibitors has been described

D.09 Tutoring for postgraduate students

COBISS.SI-ID: 2181233